Complex antithrombotic therapy: determinants of patient preference and impact on medication adherence

Neena S Abraham1, Aanand D Naik2, Richard L Street3

  • 1Division of Gastroenterology, Mayo Clinic, Scottsdale, AZ, USA ; Divison of Healthcare Policy and Research, Department of Health Services Research, Rochester, MN, USA.

Insights

Complex antithrombotic therapy (CAT) involves trade-offs. Adaptive conjoint analysis (ACA) helps patients clarify preferences, leading to better medication adherence and engagement.

Area of Science:

  • Gerontology
  • Cardiology
  • Pharmacology

Background:

  • Older adults often receive complex antithrombotic therapy (CAT) to prevent cardiovascular events.
  • While beneficial, CAT increases the risk of adverse bleeding events.
  • Balancing benefits and risks is crucial for patient well-being and adherence.

Purpose of the Study:

  • To assess patient-reported trade-offs between cardioprotective benefits, bleeding risks, and self-management burden using adaptive conjoint analysis (ACA).
  • To examine the clinical application of ACA in eliciting patient preferences for CAT.
  • To determine the impact of ACA on medication adherence.

Main Methods:

  • An electronic ACA survey presented 201 respondents with medication risk-benefit trade-offs.
  • Patient preferences for CAT risk/benefit profiles were identified.
  • Medication adherence was measured using VA pharmacy refill data before and 1 year after preference elicitation.
  • Qualitative interviews explored patient perceptions of ACA.

Main Results:

  • Participants prioritized 5-year cardiovascular benefit over preventing adverse events.
  • Bleeding risk and cardioprotective benefits were more important than side effects or regimen complexity.
  • One year post-ACA, adherence increased by 15% in patients with preference-concordant CAT strategies, versus 6% for discordant strategies.
  • Qualitative data indicated ACA increased patient activation, preference awareness, and engagement with clinicians.

Conclusions:

  • Adaptive conjoint analysis (ACA) empowers patients to clarify preferences regarding complex antithrombotic therapy (CAT) risks, benefits, and self-management.
  • Medication regimens aligned with patient preferences demonstrated significantly higher adherence at 1 year.
  • ACA enhances patient engagement, improving adherence through a better understanding of treatment preferences.
Abstract

Related Concept Videos

Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
415
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
465
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
332
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
168